ASPIRE Workshop 1: Conceiving the Research Idea

Slides:



Advertisements
Similar presentations
Medication Management
Advertisements

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.
Medication Therapy Management: Methods to Increase Comprehensive Medication Review Participation Harrell T, RPh, Diaz M, PharmD Candidate, Ortega Y, PharmD.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Maenne Okunola Pharm D Candidate: University of Georgia June 3, 2012 Preceptor Dr. Ali Rahimi.
 Grants for projects  Grants for individuals  Grants for disaster recovery projects Foundation Grants.
Residency Programs & Fellowships Angela Singh, PharmD Assistant Professor of Pharmacy Practice Florida A&M University College of Pharmacy.
ACCP Cardiology PRN Journal Club
LDL Program Medical Management Philip E. Johnston, Pharm.D.
Clinical Pharmacy Part 2
Nursing Research Capacity Building. Background CON –opened as 9 th College at SQU in 2008 The CON’s next challenge is promoting nursing care based on.
AIM Statement The use of reminders to eligible patients in the Resident Clinic to have a mammogram will improve rates of screening. Over a 6 month period,
Enter Title of Presentation Here Presenter Name Optional Information: School, Position.
AA-4-1 Patricia A. Kriger Senior Director Rx to OTC Marketing 7asdf.
“USAPI-PHARMACY ASSOCIATION - RESPONSE TO NCD ROADMAP” Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa 51 st 1-18 nov 2011 Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa.
Developing a Research Question Judy Zerzan, MD, MPH July 5, 2005.
ST ELEVATION MYOCARDIAL INFARCTION (STEMI) PATIENT DISCHARGE INSTRUCTION CHECKLIST: CAN WE DO BETTER? Maryann Rabusic-Wiedener, Shauna Johns, Tina Ainsworth,
ASPIRE CLASS 1: Conceiving the Research Idea
Welcome and please sign in! MOUNT AUBURN PRACTICE IMPROVEMENT PROGRAM (MA-PIP) Practice Managers Session June 11, 2015.
Overview of VCS Interfaces Amanda Wright Community First.
ASPIRE Workshop 4: Study Procedures and Data Elements, Sources, Uses, and Issues Kari L Olson, BSc(Pharm), Pharm D, FCCP, BCPS.
Mexican Institute of Social Security A Multifaceted Continuing Medical Education Intervention to Improve Primary Care Physicians’ Performance In Mexico.
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
Documentation in Practice Dept. of Clinical Pharmacy.
COMMUNITY PHARMACY WORKBOOK PUBLIC HEALTH DORSET
University of Southern Mississippi
ACE Curriculum 2015 The research question
Meeting Monday November 7, :00 – 11:30 am.
ASPIRE Workshop 3: Choosing Your Study Design and Population
ASPIRE Session 3: Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS.
NHSE Diabetes Prevention Programme (NDPP)
Role of The Physical Therapist in Critical Inquiry
Critical Care Services Pharmacist Royal Manchester Children’s Hospital
Can Primary Care Physicians Learn and Adopt Brief Motivational Interviewing Techniques in their Practice? Alan Adelman, MD, MS David Richard, MD Robert.
Leigh E. Tenkku, PhD, MPH Department of Family and Community Medicine
Instructions for making a CLIPS Card:PREVENTION
Safi U. Khan MD; John Pamula MD
Introduction to Clinical Pharmacy
ASPIRE Workshop 4: Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS.
Article IV Special Projects Supplemental Instruction (SI) FY 2017
Instructions for making a CLIPS Card:PREVENTION
Impact of Academic Detailing in the Chicagoland Region: A Pilot Study
ASPIRE Workshop 5: Application of Biostatistics
Polypharmacy In Adults: Small Test of Change
Criteria for Student’s PowerPoint Presentations for Student Led Conferences Lesson # 5 Explain to students that they are going to be learning what their.
ASPIRE Workshop 5: Application of Biostatistics
PCSK9 Inhibitors Post-CVOTs
ASPIRE Workshop 1: Conceiving the Research Idea
Impact of a public education program on promoting rational use of medicines:
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
PCSK9 Inhibitors and Cardiovascular Outcomes
Therapeutic Drug Management Quality Project
Role of The Physical Therapist in Critical Inquiry
AromaTouch Technique July 2017 Study Results
Primum non nocere Olabisi Oshikanlu M.D., F.A.A.P
Instructions for making a CLIPS Card:PREVENTION
Candice Preslaski, PharmD, BCPS, BCCCP
Pharmacy practice and the healthcare system Ola Ali Nassr
ASPIRE CLASS 1: Conceiving the Research Idea
Development of a Direct Oral Anticoagulant Monitoring Service in a Family Medicine Clinic Caprisse Honsbruch, Leah Mouw, Zachary Mulford, Jay Tieri, Sara.
The Research Question Background: Question:
COMMUNITY PHARMACY WORKBOOK 2019 PUBLIC HEALTH DORSET
ASPIRE Workshop 2: Choosing Your Study Design and Population
ASPIRE Workshop 5: Application of Biostatistics
Behavioral Health Clinic Quality Measures (BHCQMs)
Your Title HEre Your Name.
PCSK9 Inhibitors and Real-World Evidence
University of Southern Mississippi
Presentation transcript:

ASPIRE Workshop 1: Conceiving the Research Idea Katie Derington, PharmD Outcomes Research Fellow in Ambulatory Care Kaiser Permanente Colorado & University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

What to Expect from this program Just-in-time structured instruction on research principles Professional and peer feedback on your project Accountability assistance

What is Expected of you? Come to workshops prepared Participate in the large & small group workshops Post-class meeting with local preceptor(s) IRB training +/- IRB attendance

What to Expect Today Large Group Workshop Small Group Workshop Session Evaluation

Resources ASPIRE website ASPIREKPCO.weebly.com Small Group Mentor Local Research Preceptor

http://www.ASPIREKPCO.WEEBLY.COM

Conceiving a Research Question Background: Current ACC/AHA Guidelines recommend statin therapy in patients with T2DM over 40 years of age and an ASCVD risk score > 7.5% There are hundreds, maybe thousands of DM patients in our system who meet this criteria and are NOT on a statin

Conceiving a Research Question Can letters to patients serve as a population management strategy to get eligible T2DM patients onto statin therapy?

PICO Population Intervention Comparison Outcome(s)

Population* T2DM ASCVD > 7.5% No statin therapy in past year

Intervention* Send eligible patients a letter explaining benefits of statin therapy Ask patient to pick up Rx for a statin (already ordered) Include a phone number to ask a pharmacist any questions

Comparison* Patients not receiving this intervention

Outcome* Purchase of a statin Rx within 3 months of letter mail date

Refined study question Among T2DM patients likely to benefit from statin therapy, will an intervention involving a letter, a pre-ordered statin prescription, and pharmacist counseling significantly increase statin initiation compared to no intervention?

FINER Feasibility Interesting Novel Ethical Relevant

Objectives Primary: Secondary: Quantify the effect of the intervention on the rate of “statin starts” within 3 months of letter mail date (=index date) Secondary: Among statin-starters, compare persistence at 1 year Among statin-starters, compare proportion with an elevated CK or ALT during the 6-mo post-index

Primary Objective Compare short-term efficacy… Outcome: number of statin starts (Defined as: purchase of a statin Rx within 3 months of index date) Hypothesis: More patients in the intervention group will start statins compared to those in the no intervention group

Secondary Objectives Compare longer term efficacy… Outcome: Statin persistence (Defined as: statin purchase at one year post-index date ± 45 days) Hypothesis: There will be similar rates of statin persistence at one year among statin-starters in each group

Secondary Objectives Compare safety… Outcome: Number of individuals with CK > 600 IU/L or ALT > 200 IU/L during 6 months post-index date in each group Hypothesis: The incidence of abnormal CK or ALT levels will be similar between the two groups

Questions?